Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates
Authors:
- Mary R. DicklinMDMary R. Dicklin
- 1 March 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 22 (2) , 116-123
Abstract
To describe recent strategies that have been developed to enhance absorption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from dietary supplements. The long-chain omega-3 fatty acids EPA and DHA have important physiologic functions, and numerous potential health benefits have been suggested by results from observational studies and randomized, controlled trials. EPA and DHA intakes in the average American diet are substantially below recommended levels. Dietary supplements are available for consumers wishing to increase their intakes, but many of these are in ethyl ester formulations from which EPA and DHA are poorly absorbed when consumed without a meal containing dietary fat. Technologies have been developed to enhance EPA and DHA absorption through in-situ emulsification, which facilitates bioavailability, even in the absence of a fat-containing meal. Findings from randomized controlled trials of absorption enhancers incorporated into omega-3 fatty acid supplements demonstrate that they can markedly improve the bioavailability of EPA and DHA. The development of absorption enhancement technology to increase bioavailability of long-chain omega-3 fatty acids has important implications for studies on the health effects of dietary supplement and pharmaceutical products containing EPA and/or DHA.Keywords
This publication has 34 references indexed in Scilit:
- Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II studyVascular Health and Risk Management, 2013
- Bioavailability of long-chain omega-3 fatty acidsProstaglandins, Leukotrienes and Essential Fatty Acids, 2013
- Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older AdultsAnnals of Internal Medicine, 2013
- A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) studyJournal of Clinical Lipidology, 2012
- Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fishThe American Journal of Clinical Nutrition, 2012
- Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid contentProstaglandins, Leukotrienes and Essential Fatty Acids, 2012
- Omega-3 Fatty Acids and Cardiovascular DiseaseJACC, 2011
- Enhanced Absorption of n-3 Fatty Acids from Emulsified Compared with Encapsulated Fish OilJournal of the American Dietetic Association, 2009
- Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat mealBiochemical and Biophysical Research Communications, 1988
- Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl estersBiochemical and Biophysical Research Communications, 1988